



PLAN REVIEW


PHARMACY BENEFIT PERFORMANCE



Start Date: **1/1/2022** - End Date: **12/31/2022**



PLAN REVIEW AGENDA





PLAN SUMMARY

...

Review of Plan Sponsor
Pharmacy Benefit
Performance



PLAN COST SUMMARY



Key Performance Indicators (KPI)	Current Period	Previous Period	% Change (L/Y)
Membership			
Utilizing Member Count	5,225	4,936	▲ 5.85%
Member Paid	\$983,736	\$885,026	▲ 11.15%
Member Share %	5.45%	5.20%	▲ 0.25%
Account Plan Paid PMPM	\$216.35	\$209.57	▲ 3.24%
Average Account Members	6,582	6,415	▲ 2.60%
Claims			
Total Rx Count	105,291	98,061	▲ 7.37%
Retail	94,580	87,680	▲ 7.87%
- Retail Maintenance	67,654	63,769	▲ 6.09%
Mail Order	9,335	9,112	▲ 2.45%
Specialty	1,376	1,269	▲ 8.43%
Generic Dispensing Rate (GDR)	85.11%	85.86%	▼ -0.75%

PLAN COST KPIs



KPI	Current Period	Previous Period	% Change (L/Y)
Total Rx Spend			
Total Cost	\$18,050,447	\$17,017,065	▲ 6.07%
Total Plan Paid	\$17,066,711	\$16,132,039	▲ 5.79%
Dispensing Fee	\$49,449	\$132,371	▼ -62.64%
Plan Paid			
Specialty	\$8,728,128	\$7,850,271	▲ 11.18%
Non-Specialty	\$8,338,583	\$8,281,768	▲ 0.69%
Channel (Non-Specialty Plan Paid)			
Retail	\$6,792,033	\$6,683,747	▲ 1.62%
Mail Order	\$1,546,549	\$1,598,021	▼ -3.22%




RX UTILIZATION




Detailed Review of Rx Claims
from Plan Sponsor Utilization



CHANNEL SUMMARY



Channel	Total Plan Paid	% of Total
Mail Order	\$1,546,549	9.06%
Retail	\$6,792,033	39.80%
Specialty	\$8,728,128	51.14%



TOP DRUG CLASSES



Most Common Indicator	Current				Previous			
	Utilizing Members	Rx Count	Member Paid	Plan Paid	Utilizing Members	Rx Count	Member Paid	Plan Paid
DIABETES	564	6,135	\$107,156	\$2,441,313	536	5,995	\$92,388	\$2,390,426
SKIN CONDITIONS	559	1,182	\$15,867	\$2,218,051	599	1,311	\$16,772	\$2,117,141
CANCER	67	445	\$4,992	\$1,996,731	66	388	\$5,121	\$1,806,911
INFLAMMATORY CONDITIONS	121	955	\$36,936	\$1,961,899	112	829	\$32,956	\$1,843,245
ASTHMA	880	4,242	\$71,363	\$781,928	757	3,791	\$59,346	\$766,778
ANTICOAGULANT	208	1,248	\$28,549	\$624,480	213	1,284	\$26,447	\$598,714
PULMONARY HYPERTENSION	4	47	\$1,060	\$622,580	4	48	\$1,452	\$628,284
MULTIPLE SCLEROSIS	8	79	\$1,490	\$587,183	10	99	\$2,465	\$629,574
CYSTIC FIBROSIS	3	20	\$195	\$509,676	1	10	\$700	\$246,080
BLOOD CELL DEFICIENCY	3	39	\$662	\$300,586	4	40	\$847	\$239,018
HIGH BLOOD CHOLESTEROL	1,163	7,636	\$40,279	\$279,178	1,128	6,716	\$55,166	\$249,307
SEIZURES	519	3,255	\$28,480	\$271,131	546	3,201	\$25,325	\$274,328
MENTAL/NEURO DISORDERS	149	1,022	\$11,552	\$248,978	158	1,114	\$16,865	\$183,412
HIGH BLOOD PRESSURE/HEART DISEASE	1,811	18,503	\$128,446	\$239,595	1,775	17,600	\$101,358	\$206,794
GI DISORDERS	131	477	\$12,248	\$235,801	133	443	\$11,294	\$237,115
Total	6,190	45,285	\$489,275	\$13,319,108	6,042	42,869	\$448,502	\$12,417,129

TOP DRUG CLASSES: NON-SPECIALTY



Most Common Indicator	Current				Previous			
	Utilizing Members	Rx Count	Member Paid	Plan Paid	Utilizing Members	Rx Count	Member Paid	Plan Paid
DIABETES	564	6,135	\$107,156	\$2,441,313	536	5,995	\$92,388	\$2,390,426
ASTHMA	880	4,242	\$71,363	\$781,928	757	3,791	\$59,346	\$766,778
ANTICOAGULANT	208	1,248	\$28,549	\$624,480	213	1,284	\$26,447	\$598,714
HIGH BLOOD CHOLESTEROL	1,163	7,636	\$40,279	\$279,178	1,128	6,716	\$55,166	\$249,307
SEIZURES	519	3,255	\$28,480	\$271,131	546	3,201	\$25,325	\$274,328
MENTAL/NEURO DISORDERS	149	1,022	\$11,552	\$248,978	158	1,114	\$16,865	\$183,412
HIGH BLOOD PRESSURE/HEART DISEASE	1,811	18,503	\$128,446	\$239,595	1,775	17,600	\$101,358	\$206,794
GI DISORDERS	131	477	\$12,248	\$235,801	133	443	\$11,294	\$237,115
DEPRESSION	1,266	9,167	\$61,725	\$235,555	1,212	8,436	\$52,741	\$211,434
ATTENTION DISORDERS	298	2,240	\$28,754	\$214,937	242	1,750	\$22,530	\$217,541
HIV	16	152	\$5,177	\$205,603	14	170	\$4,116	\$257,684
PAIN/INFLAMMATION	1,214	4,322	\$29,290	\$205,391	1,249	4,926	\$30,023	\$257,415
MIGRAINE HEADACHES	145	712	\$9,983	\$187,699	133	577	\$6,623	\$127,096
VACCINATIONS	1,590	2,654	\$0	\$162,184	1,713	2,922	\$0	\$137,025
WEIGHT LOSS	32	130	\$4,603	\$156,842	14	46	\$442	\$6,735
Total	9,986	61,895	\$567,606	\$6,490,614	9,823	58,971	\$504,663	\$6,121,804

To assist plan sponsors in leveraging the opportunity for reducing spend in the diabetic space, here is a summary of potential upcoming generic opportunities brand name drugs.⁸

BRAND NAME DRUG	CLASS	ADMINISTRATION/ FREQUENCY	ESTIMATED GENERIC AVAILABILITY	2021 U.S. SALES OF DRUG
Onglyza [®]	DPP4	Oral/daily	2023	\$185M
Victoza [®] ‡	GLP1	Injection/daily	2024	\$4.220B
Tradjenta [®]	DPP4	Oral/daily	2025	\$1.798B
Farxiga [®] Ⓞ	SGLT2	Oral/daily	2025	\$3.925B
Ozempic [®]	GLP1	Injection/weekly	2025	\$8.933B
Januvia [®] *	DPP4	Oral/daily	2027	\$7.520B
Trulicity [®]	GLP1	Injection/weekly	2027	\$12.912B
Invokana [®]	SGLT2	Oral/daily	2027	\$1.183B
Jardiance [®]	SLGT2	Oral/daily	2028	\$9.261B

Generic and Biosimilar Diabetes Drugs

DIABETES DRUG MARKET⁶

\$100
Billion

PREVALENCE OF DIABETES AMONG ADULTS (18+) IN THE U.S. CONTINUES TO INCREASE⁷

2011
2014
11.5%

2017
2020
13.2%

* Largest impact will be related to the launch of generics associated with Januvia[®] due to number of generic entrants and current market share.

‡ Since Victoza[®] is administered subcutaneously daily, it is not a preferred agent for patients which translates to its market share in this class. The makers of Trulicity[®] are expected to launch a new product in 2022 that may shift market share away.

Ⓞ Farxiga[®] will likely be the first in this class to become generic so preferred formulary status and market share will likely begin to shift in preparation.

TOP 10 BRAND DRUGS: NON-SPECIALTY



Product Name	Most Common Indicator	Current				Previous			
		Utilizing Members	Rx Count	Member Paid	Plan Paid	Utilizing Members	Rx Count	Member Paid	Plan Paid
Trulicity	Diabetes	88	685	\$13,645	\$742,988	78	588	\$11,274	\$624,094
Eliquis	Anticoagulant	113	543	\$18,018	\$369,998	107	503	\$14,149	\$331,821
Ozempic	Diabetes	47	289	\$7,815	\$303,965	36	200	\$7,209	\$202,744
Jardiance	Diabetes	68	425	\$11,770	\$270,128	61	369	\$11,107	\$257,242
Xarelto	Anticoagulant	46	261	\$7,346	\$206,271	48	300	\$7,514	\$201,636
Lantus	Diabetes	55	210	\$7,238	\$154,987	63	273	\$6,690	\$215,282
Januvia	Diabetes	35	166	\$5,265	\$119,636	37	191	\$6,090	\$150,853
Humalog	Diabetes	27	99	\$3,130	\$118,963	36	172	\$2,985	\$165,633
Trelegy	Asthma	28	173	\$4,932	\$109,932	22	145	\$4,415	\$91,878
Vyvanse	Attention Disorders	47	340	\$12,788	\$109,076	40	249	\$7,878	\$77,783
Total		554	3,191	\$91,947	\$2,505,944	528	2,990	\$79,310	\$2,318,966

TOP 10 GENERIC DRUGS: NON-SPECIALTY



Product Name	Most Common Indicator	Current				Previous			
		Utilizing Members	Rx Count	Member Paid	Plan Paid	Utilizing Members	Rx Count	Member Paid	Plan Paid
Mesalamine	Inflammatory Conditions	19	153	\$1,212	\$73,953	23	135	\$1,435	\$84,038
Atorvastatin Calcium	High Blood Cholesterol	610	3,565	\$15,317	\$64,311	586	3,191	\$21,823	\$39,782
Cyclosporine	Ophthalmic Conditions	21	44	\$515	\$41,792	-	-	\$0	-
Fluticasone-Salmeterol	Asthma	45	162	\$2,513	\$40,400	37	131	\$1,282	\$41,226
Buprenorphine Hcl-Naloxone Hcl	Chemical Dependence	15	131	\$3,976	\$37,097	10	111	\$1,602	\$38,677
Bupropion Hcl Er (XI)	Depression	246	1,492	\$10,816	\$32,860	217	1,236	\$9,053	\$24,536
Albuterol Sulfate Hfa	Asthma	484	918	\$6,651	\$31,809	416	763	\$5,473	\$31,682
Epinephrine	Anaphylaxis	87	100	\$1,749	\$30,929	90	114	\$604	\$39,788
Omeprazole	Heartburn/Ulcer Disease	470	2,438	\$16,312	\$29,802	491	2,531	\$14,548	\$29,242
Amphetamine-Dextroamphet Er	Attention Disorders	84	523	\$2,763	\$29,790	67	377	\$2,392	\$23,000
Total		2,081	9,526	\$61,824	\$412,743	1,937	8,589	\$58,212	\$351,971

SPECIALTY SUMMARY




Specialty Plan Paid
\$8,728,128

Specialty Rx Count
1,376

Specialty % of Total Plan Paid 51.14%

Specialty % of Total Rx Count 1.31%



TOP 10 SPECIALTY DRUGS



Product Name	Most Common Indicator	Current				Previous			
		Utilizing Members	Rx Count	Member Paid	Plan Paid	Utilizing Members	Rx Count	Member Paid	Plan Paid
Stelara	Skin Conditions	12	45	\$2,500	\$1,110,473	8	39	\$2,065	\$958,765
Humira	Inflammatory Conditions	15	142	\$7,145	\$1,023,786	15	131	\$14,894	\$872,010
Orenitram	Pulmonary Hypertension	1	24	\$980	\$606,369	1	26	\$1,249	\$611,391
Trikafta	Cystic Fibrosis	3	20	\$195	\$509,676	1	9	\$630	\$221,661
Taltz	Skin Conditions	5	60	\$1,830	\$397,391	6	68	\$2,970	\$432,521
Dupixent	Skin Conditions	9	99	\$2,301	\$350,237	10	97	\$2,210	\$324,387
Inlyta	Cancer	1	22	\$550	\$341,030	1	12	\$480	\$208,552
Xtandi	Cancer	2	24	\$460	\$302,337	3	24	\$506	\$298,899
Promacta	Blood Cell Deficiency	2	26	\$337	\$271,430	2	24	\$492	\$211,506
Otezla	Inflammatory Conditions	7	62	\$1,825	\$268,226	7	69	\$1,230	\$274,103
Total		57	524	\$18,123	\$5,180,954	54	499	\$26,726	\$4,413,796



CLINICAL



Review of Key Disease
States and Clinical Programs

Industry Trends:

BIOSIMILARS & GENERICS

The 2021 U.S. Generic and Biosimilar Medicines Savings Report, published by the Association for Accessible Medicines, found that the U.S. healthcare system saved \$338 billion in 2020 through the use of generic and biosimilar drugs.³

BIOSIMILAR

A biosimilar is a biologic* that has no clinically meaningful difference from another biologic that's already FDA-approved. Biosimilars are administered the same way as the biologic medication and have the same strength, dosage form, and potential side effects as the biologic medication.

* A biologic drug is a medication that is derived from a living organism, this can include animal cells and microorganisms, such as yeast and bacteria.

INTERCHANGEABILITY

An interchangeable biosimilar product may be substituted without the intervention of the prescriber of the reference product, much like how generic drugs are routinely substituted for brand name drugs. Interchangeability also offers one year of exclusivity for the first biosimilar of each product to receive the designation.

Biologics are one of the fastest growing prescription drug categories. The FDA approval of additional biosimilar and interchangeable biosimilar medications may help increase competition. This will allow patients to have more treatment options and potentially less expensive alternatives.⁴

GENERICS

By monitoring upcoming generic launches, ProAct can strategize appropriately, and implement formulary changes to transition utilization toward the agent losing exclusivity or by evolving our clinical programs to increase utilization.




#1 INDICATION: DIABETES

Total Plan Paid
\$2,441,313

Total Rx Count
6,135

% of Total Plan Paid 14.30%

% of Total Rx Count 5.83%



Product Name	Total Plan Paid	Total Rx Count	Utilizing Members
Trulicity	\$742,988	685	88
Ozempic	\$303,965	289	47
Jardiance	\$270,128	425	68
Lantus	\$154,987	210	55
Januvia	\$119,636	166	35
Humalog	\$118,963	99	27
Farxiga	\$103,368	169	27
Novolog	\$76,850	60	17
Tresiba	\$61,261	75	12
Toujeo	\$58,023	53	10


#2 INDICATION: SKIN CONDITIONS

Total Plan Paid
\$2,218,051

Total Rx Count
1,182

% of Total Plan Paid 13.00%

% of Total Rx Count 1.12%



Product Name	Total Plan Paid	Total Rx Count	Utilizing Members
Stelara	\$1,110,473	45	12
Taltz	\$397,391	60	5
Dupixent	\$350,237	99	9
Cosentyx	\$146,405	22	2
Tremfya	\$124,642	10	3
Skyrizi	\$37,575	2	1
Mometasone	\$247	26	22
Fluticasone	\$30	2	2
Tacrolimus	\$1,604	13	11
Metronidazole	\$4,539	68	42


#3 INDICATION: CANCER

Total Plan Paid
\$1,996,731

Total Rx Count
445


% of Total Plan Paid 11.70%

% of Total Rx Count 0.42%




Product Name	Total Plan Paid	Total Rx Count	Utilizing Members
Inlyta	\$341,030	22	1
Xtandi	\$302,337	24	2
Erleada	\$174,448	13	1
Tagrisso	\$173,047	11	1
Piqray	\$171,463	9	1
Bexarotene	\$138,341	9	1
Braftovi	\$121,497	9	1
Revlimid	\$114,540	5	1
Mektovi	\$92,584	9	1
Votrient	\$70,186	5	1

PRIOR AUTHORIZATIONS



PA Aging Time by Event Type

Event Type	Aging Time In Days	PA Count	% of Total PA Count
Initial/Primary	3.5	1,267	87.62%
Renewal	3.5	95	6.57%
Reopening	3.3	47	3.25%
First Level of Appeal	1.9	37	2.56%
Grand Total	3.0	1,446	100.00%




CLINICAL NEWS

Changes in healthcare can be non-stop and, frankly, confusing. Let ProAct keep you up-to-date! We offer important clinical news via our LinkedIn page. From regulatory compliance, FDA approvals, generic launches, and vaccine recommendations – we cover the trending topics you should know.

PROACT ProAct - PBM
1,316 followers
2mo · 🌐

On December 16, 2022, the Food and Drug Administration granted approval to Adstiladrin, the first gene therapy indicated for the treatment of adult patients with a specific form of unresponsive non-muscle-invasive bladder cancer (NMIBC). According to the manufacturer, Ferring, the gene therapy should be available in the second half of 2023. Although pricing information for Adstiladrin has not yet been announced, it is expected to have an estimated cost of \$181,000 annually and compete with Keytruda.

https://hubs.li/Q01er5_v0



First Gene Therapy Approved for Bladder Cancer

PROACT [LEARN MORE](#)

PROACT ProAct - PBM
1,316 followers
1mo · 🌐

On January 31st, Amgen introduced Amjevita™ (adalimumab) citrate-free injection, a biosimilar to Humira® (adalimumab) injection 50mg/mL. Amjevita™ is the first of several Humira® biosimilars to become available in the United States. Additional biosimilars, including some that will be classified as interchangeable with Humira®, are expected to launch in the second half of 2022. Amjevita™ is approved for treating most of the same inflammatory conditions as Humira®, with the exception of hidradenitis suppurativa and uveitis. ProAct is currently conducting a value assessment and will be adding it to our formulary within the next 60 days. Amjevita™ is available at our specialty pharmacy, Noble Health Services. Please contact your Account Manager or one of our Sales Directors for more information on ProAct's biosimilar strategy.

<https://hubs.li/Q018q0Yd>




PROACT

UPDATE: First Humira® Biosimilar Now Available in U.S.

[LEARN MORE](#)

PROACT ProAct - PBM
1,316 followers
2w · 🌐

Recently, the U.S. Centers for Disease Control and Prevention (CDC) released its updated recommendations to immunization schedules for children and adolescents 18 years of age or younger, and for adults 19 years of age or older. These schedules were previously approved by the Advisory Committee on Immunization Practices (ACIP) in October 2022. With this update, COVID-19 vaccinations were included as part of the routine immunization schedules for both children, adolescents, and adults; however, this does not mean COVID-19 vaccinations will be required by schools or workplaces. School-entry vaccination requirements are determined by state or local jurisdictions. For more information on CDC vaccination schedules, please visit: <https://hubs.li/Q01CvmdH0>



PROACT

CDC Update on Immunization Schedule Recommendations

[LEARN MORE](#)

follow us ON  @ ProAct - PBM



COVID-19 Coverage Changes


On January 30, 2023, the Biden Administration announced it will end the public health emergency (PHE) declarations related to the COVID-19 pandemic effective May 11, 2023.

In preparation for the end of the PHE, ProAct has been closely monitoring industry expectations. Here is what you should know:

- We anticipate COVID-19 vaccines will move to coverage per ACA guidelines for preventative care.
- Coverage of antivirals used to treat COVID-19 (e.g. Paxlovid®, Lagevrio®) will be determined by plan design relating to formulary placement.
- The current coverage mandated for COVID-19 test kits will be removed from your plan on May 11, 2023 — unless otherwise specified.

COVID-19

- Fully Vaccinated 469 members through the pharmacy benefit
 - 2 doses Moderna, Pfizer, Novavax and Astzen.
 - 1 dose for Janssen.
- OTC tests filled 970, total plan pay \$73,962.09
- Adjusted GDR: 86.31%



Appendix



Exhibit A: Top Pharmacies by
Plan Paid



Exhibit B: Summary By Month

Exhibit A

Top 25 Pharmacies by Plan Paid

Pharmacy Name	Pharmacy State	Rank	Rx Count	Member Cost	Plan Cost	Total Cost
NOBLE HEALTH SERVICES INC.	NY	1	1,104	\$52,868	\$5,174,282	\$5,227,150
KINNEY DRUGS	NY	2	25,599	\$188,471	\$1,846,136	\$2,034,607
PROACT PHARMACY SERVICES INC.	NY	3	9,335	\$175,634	\$1,546,549	\$1,722,183
ACCREDITO HEALTH GROUP INC	PA	9	20	\$700	\$422,604	\$423,304
	TN	4	45	\$1,005	\$893,736	\$894,741
WEGMANS FOOD MARKETS INC.	NY	5	11,852	\$78,428	\$870,305	\$948,733
WALGREENS #19370	NY	6	5,512	\$36,766	\$534,611	\$571,377
OPTUM PHARMACY 702 LLC	IN	7	33	\$1,620	\$479,002	\$480,622
CAREMARK NEW JERSEY SPECIALTY PHARMACY DBA CVS/SPE..	NJ	8	48	\$1,205	\$438,568	\$439,773
STATE UNIVERSITY OF NEW YORK OUTPATIENT PHARMACY	NY	10	72	\$750	\$277,535	\$278,285
RITE AID PHARMACY 10738	NY	11	3,420	\$27,296	\$235,692	\$262,988
CVS PHARMACY #00502	NY	12	2,895	\$23,267	\$198,452	\$221,720
WALGREENS #17195	NY	13	2,199	\$16,967	\$195,506	\$212,473
WALGREENS #19684	NY	14	2,371	\$25,059	\$193,126	\$218,185
WALGREENS #10158	NY	15	2,489	\$22,427	\$180,255	\$202,682
CVS PHARMACY #16838	NY	16	2,926	\$22,063	\$178,059	\$200,123
ASSOCIATED MEDICAL PROFESSIONALS OF NY PLLC	NY	17	21	\$210	\$174,352	\$174,562
WALGREENS #17204	NY	18	2,831	\$25,107	\$161,130	\$186,237
CVS/SPECIALTY	PA	19	17	\$585	\$159,168	\$159,753
RITE AID PHARMACY 10880	NY	20	1,194	\$19,020	\$131,901	\$150,921
WALMART PHARMACY 10-5240	NY	21	1,283	\$8,532	\$131,506	\$140,038
SUNY UPSTATE OUTPATIENT PHARMACY AT UCH	NY	22	39	\$467	\$121,104	\$121,571
WALMART PHARMACY 10-1705	NY	23	2,636	\$14,813	\$108,772	\$123,584
OPTUMRX PHARMACY 706 INC.	NY	24	14	\$375	\$95,341	\$95,716
CVS PHARMACY #02252	NY	25	1,410	\$14,243	\$95,258	\$109,501

Exhibit B

Summary by Month

	Eligible Members	Utilizing Members	Rx Count	Member Paid / Rx	Plan Paid	Plan Paid / Rx	% Generic	% Brand	% MS Brand	Plan Paid / Brand	Plan Paid / Generic	Plan Paid PMPM	Rx Count PMPM
January 2021	6,388	2,698	7,799	\$10.56	\$1,182,897	\$151.67	87%	11%	1%	\$1,324.63	\$173.75	\$185.17	1.22
February 2021	6,377	2,599	6,993	\$10.91	\$1,219,374	\$174.37	87%	12%	1%	\$1,462.08	\$201.15	\$191.21	1.10
March 2021	6,399	2,848	8,534	\$10.43	\$1,341,619	\$157.21	86%	12%	1%	\$1,286.31	\$181.89	\$209.66	1.33
April 2021	6,325	2,851	8,024	\$9.50	\$1,372,575	\$171.06	85%	13%	1%	\$1,273.26	\$200.64	\$217.01	1.27
May 2021	6,366	2,803	7,953	\$8.93	\$1,344,336	\$169.04	86%	12%	1%	\$1,370.37	\$195.85	\$211.17	1.25
June 2021	6,359	2,846	8,306	\$9.22	\$1,338,041	\$161.09	86%	12%	1%	\$1,290.30	\$186.83	\$210.42	1.31
July 2021	6,391	2,822	7,986	\$8.83	\$1,396,631	\$174.88	87%	12%	1%	\$1,514.78	\$200.67	\$218.53	1.25
August 2021	6,388	2,847	8,191	\$8.75	\$1,417,088	\$173.01	87%	12%	1%	\$1,496.40	\$198.72	\$221.84	1.28
September 2021	6,496	2,882	8,237	\$7.99	\$1,295,706	\$157.30	84%	15%	1%	\$1,071.72	\$187.02	\$199.46	1.27
October 2021	6,397	2,934	8,597	\$8.01	\$1,441,204	\$167.64	83%	16%	1%	\$1,071.53	\$201.91	\$225.29	1.34
November 2021	6,446	2,902	8,490	\$7.84	\$1,381,729	\$162.75	84%	15%	1%	\$1,093.14	\$194.09	\$214.35	1.32
December 2021	6,648	3,011	8,951	\$7.83	\$1,400,839	\$156.50	84%	15%	1%	\$1,027.01	\$187.13	\$210.72	1.35
Total:	6,415	4,936	98,061	\$9.03	\$16,132,039	\$164.51	86%	13%	1%	\$1,248.90	\$192.33	\$209.57	1.27

	Eligible Members	Utilizing Members	Rx Count	Member Paid / Rx	Plan Paid	Plan Paid / Rx	% Generic	% Brand	% MS Brand	Plan Paid / Brand	Plan Paid / Generic	Plan Paid PMPM	Rx Count PMPM
January 2022	6,513	2,878	8,467	\$11.48	\$1,249,736	\$147.60	85%	14%	1%	\$1,040.58	\$174.33	\$191.88	1.30
February 2022	6,812	2,771	7,773	\$10.64	\$1,189,020	\$152.97	86%	13%	1%	\$1,180.76	\$178.18	\$174.55	1.14
March 2022	6,566	2,974	9,086	\$11.03	\$1,407,750	\$154.94	86%	12%	1%	\$1,245.80	\$179.58	\$214.40	1.38
April 2022	6,520	2,966	8,916	\$9.43	\$1,469,018	\$164.76	85%	14%	1%	\$1,162.20	\$194.78	\$225.31	1.37
May 2022	6,468	3,066	9,065	\$8.83	\$1,280,782	\$141.29	86%	13%	1%	\$1,083.57	\$164.86	\$198.02	1.40
June 2022	6,472	3,012	8,863	\$9.37	\$1,503,198	\$169.60	86%	13%	1%	\$1,351.80	\$197.09	\$232.26	1.37
July 2022	6,484	2,820	8,239	\$9.03	\$1,388,834	\$168.57	86%	13%	1%	\$1,302.85	\$196.77	\$214.19	1.27
August 2022	6,461	3,035	8,993	\$9.05	\$1,517,929	\$168.79	86%	13%	1%	\$1,340.93	\$196.32	\$234.94	1.39
September 2022	6,445	3,027	8,715	\$8.30	\$1,516,279	\$173.99	83%	16%	1%	\$1,109.20	\$209.84	\$235.26	1.35
October 2022	6,666	3,075	9,177	\$8.06	\$1,531,843	\$166.92	81%	18%	1%	\$946.17	\$206.00	\$229.80	1.38
November 2022	6,459	3,073	8,914	\$8.76	\$1,552,373	\$174.15	84%	15%	1%	\$1,165.45	\$208.20	\$240.34	1.38
December 2022	7,112	3,056	9,083	\$8.40	\$1,459,949	\$160.73	85%	14%	1%	\$1,168.89	\$188.94	\$205.28	1.28
Total:	6,582	5,225	105,291	\$9.34	\$17,066,711	\$162.09	85%	14%	1%	\$1,164.09	\$191.22	\$216.35	1.33



ANY QUESTIONS?

"As your Account Manager, I am committed to meeting your needs through fluid communication and effective program management. It is my sole focus to maximize the benefits of the PBM program by leveraging our capabilities to add value that exceeds your expectations."

Morgan Randazzo

Account Manager

(315) 413-7780, ext 3697

MorganRandazzo@ProActRx.com

6333 Route 298, Suite 210

East Syracuse, New York 13057